Feds Say Dr. Drew Was Paid By Glaxo To Talk Up Antidepressant
(FORBES) Part of the case made by U.S. prosecutors that led to GlaxoSmithKline‘s $3 billion settlement today is that the company used a network of paid experts, speaking to doctors and to the press, to promote uses of its drugs that had not been approved by the Food and Drug Administration. According to the Department of Justice’s complaint, one of those paid experts was celebrity physician Dr. Drew Pinsky, then the host of the radio show Loveline, which was also being broadcast on MTV. Pinsky has gone on to hostCelebrity Rehab, Dr. Drew on HLN, and Dr. Drew’s Lifechangers on the CW.
The government alleges that Pinsky was paid a total of $275,000 over just two months – March and April 1999 – to deliver messages about Wellbutrin SR, a Glaxo antidepressant, “in settings where it did not appear that Dr. Pinsky was speaking for GSK.”
As an exhibit to the complaint, the prosecutors include invoices from Cooney Waters, a public relations firm, to GlaxoSmithKline for Pinsky’s services as a spokesperson. They also include a transcript of Pinsky’s appearance on David Essel – Alive!, another national radio program. As part of the $3 billion settlement announced today, Glaxo agreed to pay $727 million in criminal fines for its marketing of Wellbutrin SR and Paxil, another antidepressant.
One difference between Glaxo’s Wellbutrin SR and other antidepressants is that it may not decrease libido and may actually boost sex drive. (The drug’s package insert lists both “decreased libido” and “increased libido” as potential side effects.) Most common antidepressants, like Eli Lilly’s Prozac, Pfizer‘s Zoloft, and Glaxo’s own Paxil, all of which are known as selective serotonin reuptake inhibitors (SSRIs), tend to decrease sex drive. But Glaxo had no FDA approval for promoting Wellbutrin as having fewer sexual side effects. So it allegedly paid speakers, like Pinksy, who spoke about how, in his clinical practice, he used Wellbutrin SR in patients who suffered low sex drive on other drugs.
According to the transcript, the Essel show began with a clip from a woman who said she had 60 orgasms in a row, “just nonstop.” When asked if this was even possible, Pinsky replied, “Oh yeah. For some women. What I think she was amazed about was it just suddenly started and that kind of thing most typically happens from medication, frankly.” He then segues into saying that that is what he is on the show to talk about. Soon he’s talking about how Wellbutrin (he also mentions the generic name, bupropion) is the medicine he’s had the most experience with in his practice when it comes to avoiding the sexual side effects of antidepressants. “It actually is the one we advocate, one of the things we suggest people do if they’re getting a decrease in their libido or decrease in their arousal which typically occurs in the serotonin re-uptake inhibitor medication.”
A note from the PR firm accompanying the transcript says: “During the fifteen-minute segment, Dr. Pinsky communicated key campaign messages.” The spot is almost a textbook for the way drug companies have used speakers to promote medicines. Everything Pinksy says is reasonable – anecdotally, Wellbutrin does seem to have few sexual side effects. But Pinsky’s comments has the effect of giving air time to a use of a medicine that Glaxo was not supposed to promote.
Dr. Drew wasn’t alone. He’s one of a long list of experts listed in the complaint that the government says were paid by Glaxo as part of its promotional efforts. Requests for comment were sent to a manager for Pinsky, a publicist who had represented him, and through his HLN web site, but were not immediately returned.
Invoices to Glaxo from the public relations firm Cooney Waters for paying Dr. Drew’s speaking fees.
Update: The first reporter to notice this appears to be Dan Nguyen of ProPublica, in this tweet.
Update 2: Both Pinsky and GlaxoSmithKline have responded to the questions I asked them yesterday. Pinsky, through an emailed comment sent via a spokeswoman, writes: “In the late 90s I was hired to participate in a 2 year initiative discussing intimacy and depression which was funded by an educational grant by Glaxo Wellcome. Services for the non branded campaign included town hall meetings, writings and multi media activities in conjunction with the patient advocacy group the National Depressive and Manic Depressive Association (NDMDA). My comments were consistent with my clinical experience.”
Glaxo says: “The complaint does not reflect what would be allowed in GSK today. We continually evolve and improve our business practices to align to the expectations of society and government and to our values of transparency, integrity, respect and focus on the patient. We have increased our controls to require disclosure of financial relationships of HCPs and the company. We voluntarily have posted those on our website for the past few years.”